Susquehanna Fundamental Investments’s Precision BioSciences DTIL Stock Holding History

Susquehanna Fundamental Investments’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-482	Closed	-$19K	–	1272
2022 Q3	$19K	Buy	+482	New	+$22.9K	﹤0.01%	1405
2022 Q1	$153K	Sell	1,658 -545	-25%	-$74K	﹤0.01%	1408
2021 Q4	$489K	Buy	2,203 +965	+78%	+$270K	0.01%	927
2021 Q3	$428K	Buy	1,238 +462	+60%	+$157K	0.01%	1271
2021 Q2	$291K	Sell	776 -691	-47%	-$208K	0.01%	1381
2021 Q1	$456K	Buy	+1,467	New	+$514K	0.01%	1176

Other funds holding DTIL

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna Fundamental Investments's DTIL Position: Q4 2022 in Review

Susquehanna Fundamental Investments sold out of Precision BioSciences (DTIL) in Q4 2022, closing a stake of 482 shares — an estimated $19K sold.

Susquehanna Fundamental Investments first reported a position in DTIL in Q1 2021 and held it in 6 quarters. The position peaked at $489K in Q4 2021. 100 funds tracked by Wall St. Rank hold DTIL as of Q4 2022.

Susquehanna Fundamental Investments reported no remaining Precision BioSciences position as of Q4 2022 after selling out during the quarter.
Susquehanna Fundamental Investments sold 482 Precision BioSciences shares in Q4 2022, an estimated $19K.
Susquehanna Fundamental Investments first reported a position in Precision BioSciences in Q1 2021 and held it in 6 quarters.
Susquehanna Fundamental Investments's Precision BioSciences position peaked at $489K in Q4 2021.
100 funds tracked by Wall St. Rank held Precision BioSciences as of Q4 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2022, filed 14 Feb 2023.